Cara Therapeutics Files 8-K/A Amendment

Ticker: TVRD · Form: 8-K/A · Filed: Dec 20, 2024 · CIK: 1346830

Cara Therapeutics, Inc. 8-K/A Filing Summary
FieldDetail
CompanyCara Therapeutics, Inc. (TVRD)
Form Type8-K/A
Filed DateDec 20, 2024
Risk Levellow
Pages7
Reading Time8 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: amendment, exhibits, filing

TL;DR

Cara Therapeutics filed an amendment to an 8-K, likely correcting or adding exhibit details.

AI Summary

Cara Therapeutics, Inc. filed an 8-K/A on December 20, 2024, to amend a previous filing. The amendment pertains to Item 9.01, Financial Statements and Exhibits, related to the company's business operations. No specific financial figures or new material events were detailed in this amendment.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for understanding the company's official disclosures.

Risk Assessment

Risk Level: low — This is a procedural amendment to a previous filing, not announcing new material events or financial results.

Key Players & Entities

  • Cara Therapeutics, Inc. (company) — Registrant
  • 0001104659-24-130803 (filing_id) — Accession Number
  • December 17, 2024 (date) — Earliest event reported
  • December 20, 2024 (date) — Filing Date
  • 400 Atlantic Street Suite 500 Stamford, CT 06901 (address) — Principal executive offices

FAQ

What is the purpose of this 8-K/A filing?

This 8-K/A filing is an amendment to a previously filed 8-K report, specifically addressing Item 9.01, Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The earliest event reported is dated December 17, 2024.

When was this 8-K/A filing submitted to the SEC?

The filing was submitted on December 20, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 400 Atlantic Street, Suite 500, Stamford, CT 06901.

What is the Central Index Key (CIK) for Cara Therapeutics, Inc.?

The Central Index Key for Cara Therapeutics, Inc. is 0001346830.

Filing Stats: 2,031 words · 8 min read · ~7 pages · Grade level 15.2 · Accepted 2024-12-20 16:05:18

Key Financial Figures

  • $0.001 — ge on which registered Common Stock, $0.001 par value per share CARA The Nasdaq

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1* Agreement and Plan of Merger and Reorganization, dated December 17, 2024, by and among Cara Therapeutics, Inc., CT Convergence Merger Sub, Inc. and Tvardi Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Original Form 8-K) 10.1 Form of Cara Therapeutics, Inc. Stockholder Support Agreement, dated December 17, 2024 (incorporated by reference to Exhibit 10.1 to the Original Form 8-K) 10.2 Form of Tvardi Therapeutics, Inc. Stockholder Support Agreement, dated December 17, 2024 (incorporated by reference to Exhibit 10.2 to the Original Form 8-K) 10.3 Form of Lock-Up Agreement, dated December 17, 2024 (incorporated by reference to Exhibit 10.3 to the Original Form 8-K) 10.4* Asset Purchase Agreement, dated December 17, 2024, by and among Cara Therapeutics, Inc. Cara Royalty Sub, LLC and Vifor Fresenius Medical Care Renal Pharma, Ltd. (incorporated by reference to Exhibit 10.4 to the Original Form 8-K) 99.1 Joint Press Release of Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc. issued on December 18, 2024 (incorporated by reference to Exhibit 99.1 to the Original Form 8-K) 99.2 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) or 601(b)(2) of Regulation S-K, as applicable. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ Ryan Maynard Ryan Maynard Chief Financial Officer Dated: December 20, 2024

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.